They are not reviewed by the FDA for safety, effectiveness, or manufacturing quality
Lisa Stevens, chief administrative officer for Aon, said, Its been important to include GLP-1 coverage as part of our own US Total Rewards strategy. She noted that the decision reflects how employer choices today affect the health and performance of their workforces
Data are partially retrieved from the approved list of DPP inhibitors by the US Food and Drug Administration (FDA) ( Shortcomings associated with DPP-IV inhibitors The previous studies revealed the most common adverse effects in patients, including infections in the respiratory passage, nasopharyngitis, headache, and bladder infections associated with sitagliptin and saxagliptin, respectively ( On a wider scale, strong aversions were laid against incretin-based therapy regarding its cost-effectiveness and the increasing risk of morbidity in patients with cardiovascular issues ( Pharmacognosy: A strategy to alleviate the glycemic load Since antiquity, many traditional practitioners across the globe have assertively exploited natural flora, which has proven superlatively therapeutic over synthetic agents to regulate several pathological conditions
Report any suspected side effects via the MHRA Yellow Card Scheme, particularly important for investigational medicines
